Instil Bio, Inc.
About Instil Bio, Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2021
- $0
- Net income
- -$71.4M
- Total assets
- $203.5M
- Market cap
- $54.7M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $78.6M
- Operating income
- -$78.6M
- Income tax
- $0
- Net income
- -$71.4M
- EPS (basic)
- $-10.70
- EPS (diluted)
- $-10.70
Balance sheet
- Total assets
- $203.5M
- Current assets
- $191.4M
- Total liabilities
- $89.7M
- Current liabilities
- $4.8M
- Shareholders’ equity
- $113.9M
Cash flow
- Operating cash flow
- -$36.6M
- Investing cash flow
- $25.5M
- Financing cash flow
- $7.3M
- Net cash flow
- -$3.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $54.7M
- EPS (diluted)
- $-10.7
- Shares outstanding
- 6.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 19, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $71.4M in FY2021.
- Trading 78% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Instil Bio, Inc..
Write a review
News about Instil Bio, Inc.
News & sentiment via Polygon.io
